Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of hypertension comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hypertension for each…

Clarivate Epidemiology’s coverage of hypertension comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hypertension for each…

Clarivate Epidemiology’s coverage of hypertension comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hypertension for each…

Clarivate Epidemiology’s coverage of hypertension comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hypertension for each…

Atherosclerotic cardiovascular disease (ASCVD) is caused by plaque buildup in arterial walls. Clinical / established ASCVD consists of acute coronary syndromes, a history of myocardial infarction (…

The market for NASH, a severe form of nonalcoholic fatty liver disease (NAFLD), offers substantial commercial opportunity to drug developers owing to the lack of approved agents and the disease’s…

The type 2 diabetes (T2D) therapy market will expand over the first half of the 2021-2031 forecast period. This increase will be partly fueled by a rich pipeline of novel agents; emerging therapies…

Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative market for pharmacotherapies owing to the lack of approved agents and the disease’s relatively high prevalence…

NASH has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis,…

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder marked by considerable morbidity and mortality. Despite the availability of a wide array of drugs for PAH, substantial…

Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at…

Congenital heart block (CHB), also known as atrioventricular block, is a rare heart block disorder in which maternal antibodies attack the impulse-generating heart muscles of fetuses and newborns…